Cite
Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity.
MLA
Sengupta, Jay, et al. “Implantable Cardioverter-Defibrillator FDA Safety Advisories: Impact on Patient Mortality and Morbidity.” Heart Rhythm, vol. 9, no. 10, Oct. 2012, pp. 1619–26. EBSCOhost, https://doi.org/10.1016/j.hrthm.2012.07.002.
APA
Sengupta, J., Kendig, A. C., Goormastic, M., Hwang, E.-S., Ching, E. A., Chung, R., Lindsay, B. D., Tchou, P. J., Wilkoff, B. L., Niebauer, M. J., Martin, D. O., Varma, N., Wazni, O., Saliba, W., Kanj, M., Bhargava, M., Dresing, T., Taigen, T., Ingelmo, C., & Bassiouny, M. (2012). Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity. Heart Rhythm, 9(10), 1619–1626. https://doi.org/10.1016/j.hrthm.2012.07.002
Chicago
Sengupta, Jay, Arthur C. Kendig, Marlene Goormastic, Eui-Seock Hwang, Elizabeth A. Ching, Roy Chung, Bruce D. Lindsay, et al. 2012. “Implantable Cardioverter-Defibrillator FDA Safety Advisories: Impact on Patient Mortality and Morbidity.” Heart Rhythm 9 (10): 1619–26. doi:10.1016/j.hrthm.2012.07.002.